Search Results for: Doug Melton

Harvard’s Doug Melton Blockbuster Discovery of Hormone Betatrophin: Possible Future Diabetes Treatment?

UPDATE: Unfortunately the Betatrophin paper discussed here originally back in 2013 has now largely been proven to have come to incorrect conclusions (for more read this). Today Harvard Stem Cell Institute (HSCI) reported the discovery, in a paper in Cell by Harvard Professor Doug Melton, of a powerful new hormone called Betatrophin that can stimulate …

Harvard’s Doug Melton Blockbuster Discovery of Hormone Betatrophin: Possible Future Diabetes Treatment? Read More »

Weekly reads: Melton leaves Harvard, Fuji, BBC blunder, stem cell niche, more

Senolytics restore the stem cell niche in the brains of mice. Fatt, et al. Stem Cell Reports 2022.

Sometimes a post here on The Niche (named after the stem cell niche) sparks a debate between expert stem cell researchers and often that gives much more depth to a topic. Such was the case with my post this week on where things stand with stem cell therapy for heart disease. It led to a …

Weekly reads: Melton leaves Harvard, Fuji, BBC blunder, stem cell niche, more Read More »

ViaCyte CEO Laikind Interview: Trial Update, Melton, & Future

VC-01-post-implant-final1-e1503703572933, viacyte

It’s been exciting to watch the recent developments in using stem cells as the basis for treatments for Type I Diabetes. One of the major players in this arena is the privately-held company, ViaCyte. In this post, I interview ViaCyte President and CEO, Paul Laikind. The topics include their VC-01 product, the Encaptra device, an update on …

ViaCyte CEO Laikind Interview: Trial Update, Melton, & Future Read More »

In big shift Dr. Robert Lanza exits Astellas

Dr. Robert Lanza

The recent news of Vertex Pharma buying small stem cell biotech ViaCyte and Doug Melton moving to Vertex brought to mind an old stem cell biotech called Advanced Cell Technology (ACT) and its leader, stem cell biologist Dr. Robert Lanza. Years ago, big pharma firm Astellas bought ACT and Lanza moved to be a leader of regenerative …

In big shift Dr. Robert Lanza exits Astellas Read More »

ViaCyte purchase puts Vertex in driver’s seat on stem cells for diabetes

Doug Melton, Vertex, ViaCyte

When I’m asked about the most promising areas of stem cell clinical research, cell therapy for type I diabetes is near the top including work by a biotech called ViaCyte. Other firms are in the mix too, boosting the overall odds of success in the coming decade. It’s really that promising even though there are …

ViaCyte purchase puts Vertex in driver’s seat on stem cells for diabetes Read More »

Weekly reads: Vertex hold, new type of cell division in fish, CAR-T

zebrafish cell division

I remember the first time I ever witnessed human cell division first hand and it was really excitement. I was working as a part-time tech in the Lane Lab at UC San Diego School of Medicine. We studied heart disease and grew human umbilical cord endothelial cell cultures. It was striking to see a plate …

Weekly reads: Vertex hold, new type of cell division in fish, CAR-T Read More »

Vertex upbeat on 1st stem cell therapy for diabetes trial participant

“While still early, these results support the continued progression of our VX-880 clinical studies, as well as future studies using our encapsulated islet cells, which hold the potential to be used without the need for immunosuppression,” said Bastiano Sanna, Ph.D., executive vice president and chief of cell and genetic therapies at Vertex.

It’s hard in the cell therapy field not to get excited even with bits of seemingly encouraging news but with N=1 reports we have to be very cautious and that’s the case with news from Vertex on their 1st stem cell therapy for diabetes trial participant. Vertex stem cell therapy for diabetes VX-880: N=1 This …

Vertex upbeat on 1st stem cell therapy for diabetes trial participant Read More »

ViaCyte Q&A: CRISPR Tx quick progress, ongoing diabetes trial, & more

ViaCyte-CyT49-PSC

ViaCyte is one of the most exciting stem cell and regenerative medicine biotech companies so I like to try to check in with them regularly. Today’s post is my new interview with ViaCyte leader Paul Laikind on recent developments. We had a great chat about the science and how things are looking upbeat for the …

ViaCyte Q&A: CRISPR Tx quick progress, ongoing diabetes trial, & more Read More »

ViaCyte & CRISPR Therapeutics team up to battle diabetes

ViaCyte, cell therapy for diabetes

What happens when one of the most exciting stem cell biotechs ViaCyte teams up with a firm like CRISPR Therapeutics to use a combination of gene editing and cell therapy? Hopefully a synergistic partnership emerges that in this case can develop an effective stem cell-based therapy for diabetes. You can see a press release on …

ViaCyte & CRISPR Therapeutics team up to battle diabetes Read More »

Movers & Shakers in Stem Cell & Regenerative Medicine Field

stem-cell-movers-and-shakers

Stem Cell & Regenerative Medicine field researchers move around to different places fairly often. It is interesting to note trends and also see who received what kinds of awards and such. Below is a list of some recent movers and shakers. George Daley got the ISSCR Public Service Award (you can see other ISSCR Awards here). …

Movers & Shakers in Stem Cell & Regenerative Medicine Field Read More »